Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TLN-372 in Advanced KRAS Mutant Solid Tumors
NCT07204340Phase 1Recruiting
- Sponsor
- Treeline Biosciences
- Start
- Sep 2025
- Primary completion
- Dec 2031
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 1, open-label trial of TLN-372 in solid tumor (2 arms), sponsored by Treeline Biosciences. Primary endpoints: Dose-Limiting Toxicity at 2 years, Treatment-Emergent Adverse Events and Treatment-Related Adverse Events at 2 years and 1 more. Started Sep 2025; status: recruiting.
02
Drugs
TLN-372
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT07204340.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07204340.